In The News

In Bloomberg Law, Health Care Partner Addresses Pay-for-Delay Drug Deals

Practices: Health Care, Health Care Finance & Restructuring, Life Sciences, Managed Care, Medicare, Medicaid & Third-Party Reimbursement

Capital Insights.

Health care partner Tom Bulleit (Washington, D.C.) is quoted in a Bloomberg Law article on March 11 that examines the impact of pay-for-delay prescription drug deals.

Mr. Bulleit suggests that the proposed CREATES Act, which would give generic drugmakers modest additional tools to more quickly bring a generic to market, may be more likely to succeed than other more forceful measures that have been discussed in Congress and in President Trump’s budget.

Cookie Settings